Goldman Sachs raises Oscar Health's price target from $16.00 to $21.00, retaining a neutral rating.
Goldman Sachs raises Oscar Health's price target from $16.00 to $21.00, retaining a neutral rating. The increase follows similar updates from Raymond James, TheStreet, and Wells Fargo. Oscar Health reported Q4 EPS of $0.62, exceeding analysts' expectations by $0.34. Institutional investors hold 75.70% of the company's stock, with a market cap of $4.97B and a price-to-earnings ratio of -54.09.
May 11, 2024
3 Articles